Tron de Bouchony E, Leberre C, Dauriac C, Genetet N, Lapart C, Fauchet R, Leprisé P Y, Genetet B, Raffoux C, Semana G
Histocompatibility Laboratory, Regional Transfusion Center, Rennes, France.
Bone Marrow Transplant. 1995 Jun;15(6):845-51.
Unrelated donor searches for 100 Caucasian patients were referred to France Greffe de Moëlle Registry (FGM) from September 1987 (24,600 donors) to December 1993 (71,500 donors, 61% DR typed). After DR typing of HLA-A,B matched donors, unsuccessful searches were extended to other European Registries for 36 patients. Twenty two patients had a donor (FGM: 19, other Registries: 3) selected on: (1) HLA-A,B and DRB,DQB1 split identity; and (2) unidirectional relative response < 5% in MLR performed twice. Estimated probability of finding a compatible donor at 9 months in FGM was 12% (s.e. +/- 4%) and 25% at 2 years (s.e. +/- 6%). This probability was stringently dependent on a phenoidentity to one very common HLA-A,B,DR or B,DR haplotype (25% at 9 months when present, representing 19 of 19 patients with a compatible donor). Without this phenoidentity, the probability was zero per cent (P = 0.0001) in FGM searches and < 4% (n = 1) in extended searches. The MLR test was shown to be insensitive for screening for DPB1 mismatches. Clinical status influenced the probability of finding a compatible donor at one year ranging from 9% +/- 9% for ALL to 23% +/- 8% for CML (NS). Disregarding DPB1 mismatches is the most efficient way of increasing search efficiency.
1987年9月(24,600名供者)至1993年12月(71,500名供者,61%进行了DR分型)期间,100名白种病人的无关供者搜索被提交至法国骨髓移植登记处(FGM)。对HLA - A、B匹配的供者进行DR分型后,36名病人的未成功搜索扩展至其他欧洲登记处。22名病人有供者被选中(FGM:19名,其他登记处:3名),选择标准为:(1)HLA - A、B以及DRB、DQB1完全匹配;(2)两次混合淋巴细胞反应(MLR)中单向相对反应<5%。在FGM中,9个月时找到匹配供者的估计概率为12%(标准误±4%),2年时为25%(标准误±6%)。该概率严格依赖于与一种非常常见的HLA - A、B、DR或B、DR单倍型的表型匹配(存在时9个月时为25%,19名有匹配供者的病人中有19名符合此情况)。没有这种表型匹配时,FGM搜索中的概率为零(P = 0.0001),扩展搜索中的概率<4%(n = 1)。结果显示MLR试验对筛选DPB1错配不敏感。临床状态影响1年时找到匹配供者的概率,从急性淋巴细胞白血病(ALL)的9%±9%到慢性粒细胞白血病(CML)的23%±8%(无显著性差异)。忽略DPB1错配是提高搜索效率的最有效方法。